ASCO 2023 | Treatment intensification in metastatic castration-sensitive prostate cancer

Ravi Madan, MD, National Cancer Institute, Bethesda, MD, discusses the barriers to treatment intensification in metastatic castration-sensitive prostate cancer. Despite evidence since 2014 that standard care requires adding an anti-androgen or chemotherapy to androgen deprivation therapy (ADT), a significant proportion of patients do not receive this treatment. One barrier is the involvement of urologists in delivering care, and greater engagement of medical oncologists is suggested. Even when medical oncologists are involved, there is a tendency to delay intensification due to the initial decline in PSA levels and patient age. However, the benefits of intensification are observed in long-term survival, not immediate outcomes. Dr Ramen highlights that emphasizing the long-term benefits and promoting data dissemination among colleagues may help overcome these barriers. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.